NEW YORK (GenomeWeb) – Biodesix today announced that UnitedHealthcare has issued a positive coverage decision for the VeriStrat test for advanced non-small cell lung cancer.
UnitedHealthcare covers 44.7 million lives in the US.
VeriStrat is a blood-based proteomic test that provides prognostic and predictive data to help guide treatment of patients with advanced NSCLC. Those with VeriStrat Poor test results have a shorter medical overall survival that those with VeriStrat Good results, Boulder, Colorado-based Biodesix said.
Last month CareFirst Blue Cross Blue Shield issued a positive coverage decision for the test.